Sanofi's Vaccines Performance Helps Offset Diabetes Decline
Performance of Dupixent, which just picked up a new indication, was a third quarter highlight and bodes well for future growth, but sales of the blockbuster insulin glargine Lantus are crumbling.
You may also be interested in...
New US Cholesterol Guidelines Hit PCSK9s Hard On Pricing, Value
Already outdated? The latest ACC/AHA guidelines say at mid-2018 list prices, PCSK9 injectables are of low value, but the costs have plummeted since then.
Sanofi Stumps Up $125m To Access Denali RIPK1 Inhibitors
The French drugmaker is dipping its toe into Alzheimer's disease as part of a CNS and inflammatory alliance with Denali which could net the US firm $1bn on top of a hefty upfront fee.
Amgen Drops Repatha List Price 60% To Cut Medicare Co-Pays And Boost Use
Company says 75% of Medicare Part D patients who aren't eligible for low income subsidies abandon the PCSK9 inhibitor at the pharmacy counter due to $370 co-pay, which may now range from $25-$150 per dose.